- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01132040
Bioequivalence Study of Primidone Tablets 50 mg of Dr. Reddy's Under Fasting Conditions
May 26, 2010 updated by: Dr. Reddy's Laboratories Limited
An Open Label, Balanced. Randomized, Two-treatment, Two-period, Two-sequence, Single Dose,Crossover, Bioequivalence Study of Primidone 50 mg Tablets of Comparing With That of Mysoline® 50 mg Tablets Under Fasting Conditions.
The purpose of this study is to assess the bioavailability of Primidone 50 mg tablets of Dr.Reddy's comparing with that of Mysoline@ tablets of Yamanouchi Pharma Technologies Inc, in healthy, adult, human subjects under fasting conditions.
Study Overview
Detailed Description
An open label, balanced.
randomized, two-treatment, two-period, two-sequence, single dose,crossover, bioequivalence study of Primidone 50 mg tablets of Dr.Reddy's Laboratories Limited, Generics, India comparing with that of Mysoline (containing Primidone 50 mg) tablets of Yamanouchi Pharma Technologies Inc, Norman, OK in healthy, adult, human subjects under fasting conditions with a washout period of 14 days.
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Andhra Pradesh
-
HYD, Andhra Pradesh, India, 500 037
- Bioserve Clinical Research Pvt. Ltd,
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
Subjects must fulfill all of the following criteria to be considered for inclusion into this study:
- Subjects who will provide written informed consent.
- Subjects must be healthy, adult, human beings within 18-45 years of age (both inclusive)weighing at least 50 kg.
- Having a Body Mass Index (BMI) between 18.5 and 24.9 (both inclusive), calculated as weight in Kg/height in m2
- Subjects must be of normal health as determined by medical history and physical examination performed within 21 days prior to the commencement of the study.
- Subjects whose screening laboratory values are within normal limits or considered by the physician/investigator to be of no clinical significance.
- Availability of the subject for the entire study period and willingness to adhere to the protocol requirements as evidenced by written informed consent.
Exclusion Criteria:
The subjects will be excluded based on the following criteria during screening and during the study
- Subjects incapable of understanding the informed consent.
Subjects who have:
- Systolic blood pressure less than 90 mm ofHg or more than 140 mm of Hg
- Diastolic blood pressure less than 60 mm of Hg or more than 94 mm of Hg. Minor deviations (2-4 mm of Hg) at check-in may be acceptable at the discretion of the physician/investigator.
- Pulse rate below 50/min or above 100/min.
- History of hypersensitivity or idiosyncratic reaction to study drug or any other related drugs.
- Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal function.
- Consumption of grapefruit for the past ten days prior to the dosing day until the completion of the study.
- Regular smoker who has a habit of smoking more than nine cigarettes per day and has difficulty in abstaining from smoking from 48 hours before dosing and during sampling period.
- Subjects who have taken over the counter or prescribed medications and enzyme modifying or any systemic medication for during the last 7 and 30 days respectively before dosing.
- Subjects who have participated in any other clinical investigation using experimental drug/donated blood in past 90 days before the date of start of study.
- Subjects with clinically significant abnormalities (such as Laboratory Findings, ECG, X-Ray,Drugs of abuse, Alcohol etc.,) and/or with significant diseases (such as HIV, Hey, Syphilis,Hepatitis B etc.,).
- Female subjects who are pregnant or who are able (women with child bearing potential) to become pregnant during the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Primidone
Primidone Tablets, USP 50 mg of Dr. Reddy's Laboratories
|
Primidone Tablets, USP 50 mg of Dr. Reddy's Laboratories Limited
Other Names:
|
ACTIVE_COMPARATOR: Mysoline
Mysoline Tablets of Yamanouchi Pharma Technologies Inc,
|
Primidone Tablets, USP 50 mg of Dr. Reddy's Laboratories Limited
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Bioequivalence based on Cmax and AUC parameters
Time Frame: 2 months
|
2 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Mohanlal shiva prasad sayana, Bioserve Clinical Research Pvt. Ltd., Hyderabad, A.P.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2006
Primary Completion (ACTUAL)
September 1, 2006
Study Completion (ACTUAL)
September 1, 2006
Study Registration Dates
First Submitted
May 26, 2010
First Submitted That Met QC Criteria
May 26, 2010
First Posted (ESTIMATE)
May 27, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
May 27, 2010
Last Update Submitted That Met QC Criteria
May 26, 2010
Last Verified
May 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P-620/06
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on Primidone
-
Mutual Pharmaceutical Company, Inc.CompletedTherapeutic Equivalency
-
Dent Neuroscience Research CenterWithdrawnClopidogrel Resistance | Secondary Stroke PreventionUnited States
-
University Medical Centre LjubljanaCompletedEssential TremorSlovenia
-
Assistance Publique - Hôpitaux de ParisRecruiting